GlassScriptPhysician profile
Whitney Lynette Cline
NPI 1275670101
$1,345.81
in general payments reported to CMS, 2019-2025
31 companies · $422 in 2025
The $422 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $23.46 · 2021: $185 · 2022: $174 · 2023: $151 · 2024: $212 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $185.25 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $130.26 | 2019-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.60 | 2025 | Caplyta |
| Fresenius Kabi USA, LLC | $99.99 | 2019 | |
| Neurocrine Biosciences, INC. | $84.14 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $79.88 | 2021 | |
| Sobi, INC | $51.25 | 2022-2023 | |
| Novo Nordisk INC | $49.16 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $48.40 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $45.17 | 2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $41.87 | 2022-2025 | Abilify Asimtufii, Abilify Maintena |
| Amarin Pharma, INC. | $37.42 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $33.43 | 2022-2023 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.17 | 2019-2021 | |
| Amgen INC. | $29.90 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.66 | 2024 | Airsupra |
| Exact Sciences Corporation | $26.38 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $24.31 | 2022 | |
| Abbvie INC. | $20.20 | 2024 | |
| Xeris Pharmaceuticals, INC. | $18.59 | 2023 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $18.28 | 2021 | |
| Lilly USA, LLC | $17.25 | 2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.25 | 2021 | |
| Sanofi Pasteur INC. | $17.21 | 2022 | |
| Lundbeck LLC | $17.03 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $16.84 | 2024 | Thinprep 2000 Processor, Aptima |
| Alkermes, INC. | $16.15 | 2022 | |
| Glaxosmithkline, LLC. | $14.12 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.74 | 2023 | Jornay Pm |
| Ironwood Pharmaceuticals, INC | $12.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.